{"entity":{"id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of bevacizumab, olaparib, iparomlimab and tuvonralimab, QL2107 and other drugs in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","summary":"QLS5132 Combination Therapy in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07453394 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 626 participants, started 2026-04 and due to reach its primary completion in 2027-04. Interventions recorded: QLS5132; Bevacizumab; QLS5132; Platinum; Bevacizumab; QLS5132; Olaparib; Bevacizumab; QLS5132; QL1706; QL2107; QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin. Conditions listed: Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC); Endometrial Cancer; Advanced Solid Tumors; Ovarian Cancer. Primary outcome: Incidence and severity of adverse events; Maximum tolerated dose (MTD); Recommended Phase 2 Dose (RP2D). No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07453394","url":"https://clinicaltrials.gov/study/NCT07453394"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","monoclonal-antibody","parp-inhibitor","platinum"],"targets":[],"drugs":["bevacizumab","olaparib","iparomlimab-tuvonralimab","ql2107","carboplatin","cisplatin","capox"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07453394","phase":"1/2","setting":"A Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenous QLS5132 Combination Therapy in Participants With Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","enrolled":626,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07453394/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}